SBIR-STTR Award

A Novel HIV-1 Latency System for Drug Discovery
Award last edited on: 5/6/19

Sponsored Program
STTR
Awarding Agency
NIH : NIAID
Total Award Amount
$100,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Joseph P Dougherty

Company Information

PTC Therapeutics Inc

100 Corporate Court
South Plainfield, NJ 07080
   (908) 222-7000
   info@ptcbio.com
   www.ptcbio.com

Research Institution

University of Medicine and Dentistry of New Jersey

Phase I

Contract Number: 1R41AI060510-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2005
Phase I Amount
$100,000
Highly active antiretroviral therapy (HAART) has had an important impact upon morbidity and mortality from AIDS. Although HAART results in a remarkable suppression of HIV-1 replication in infected patients, it does not provide for elimination of the virus even after years of suppressive therapy. Contributing to the lack of viral clearance is the presence of latently infected cells in patients, which upon withdrawal of HAART, contribute to viral rebound. Attempts at eradicating latently infected cells by activating them with cytokines and lymphokines has not met with success probably owing both to the inability of this treatment to reach all of the latent viral reservoirs and to the toxicity of the regimen. Small molecules with pharmacological properties that allow them to reach all viral reservoirs and activate latent HIV-1 pro viruses could very well result in clearance of HIV-1 infections when used in combination with HAART, as HAART should control infections by the newly activated HIV-1 pro viruses while allowing elimination of the freshly activated cells because some viral proteins are cytotoxic and viral expression will induce an immune response against these cells. Here a latency vector reporter system will be developed to identify new drugs that can abrogate viral latency. T and monocyte cell lines harboring latent HIV-1 vector virus will be developed. Activation of latent virus will result in the expression of a marker gene that can be utilized for high throughput screening. This system should provide a safe, efficient and rapid system to discover novel drugs for eliminating HIV-1 infection.

Thesaurus Terms:
antiAIDS agent, drug discovery /isolation, genetic technique, high throughput technology, human immunodeficiency virus 1, latent virus infection, small molecule, technology /technique development, transfection /expression vector T lymphocyte, alkaline phosphatase, gene expression, genetic marker, host organism interaction, monocyte, provirus, virus infection mechanism biotechnology, cell line, green fluorescent protein

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----